The content on this site is intended for healthcare professionals only
Spanish Lung Cancer Group
Published: 3 Dec 2008
Views: 16558
Prof. Rafael Rosel
Benefits of customising erlotinib therapy for NSCLC.
- Categories:
- Lung & pleura
Related Videos
ASCO 2022: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
6 Jun 2022
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA ...
Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA
6 Jun 2022
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
5 Jun 2022
Latest in testing and diagnostics in exon 20 NSCLC
Dr Antonio Passaro and Prof Paul Hofman
4 Jun 2022
Ramucirumab plus pembrolizumab improves OS in advanced NSCLC
Dr Roy Herbst - Yale Cancer Center, New Haven, USA
4 Jun 2022
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year...
Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
10 May 2022
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for rese...
Prof Nicolas Girard - Institut Curie, Paris, France
10 May 2022
Recent advances in the treatment of patients with exon 20 insertion-positive NSC...
Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl
21 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
14 Apr 2022